Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes
JAMA Network Open · 24 Jul 2026
† Impact is the editorial-priority score. All scores are out of 100. Clinical is a stored clinical-importance score from the earlier method; it has not been recalculated.
Why it matters
Orthopaedic surgeons increasingly manage fragility fractures in an aging population on GLP-1 receptor agonists, and this large observational signal raises the question of whether these drugs affect bone health differently than assumed.
The evidence
This retrospective study used US electronic health records to compare 66,803 propensity-matched pairs of adults with type 2 diabetes who started either a GLP-1 receptor agonist (like semaglutide or liraglutide) or a DPP-4 inhibitor. Over 3 years, patients starting a GLP-1 RA had a 21% lower relative risk of fragility fracture than those starting a DPP-4i (hazard ratio 0.79), with the largest protection seen for vertebral and hip fractures, and this benefit appeared independent of weight loss or blood sugar changes. However, the protective effect faded by year 3, and in a separate analysis GLP-1 RA use was actually associated with higher fracture risk in people without diabetes.
incident fragility fracture: Hazard ratio 0.79 (95% CI 0.76 to 0.83; units not reported). The interval favours the first group; the size of the benefit needs clinical interpretation.
Why this rigour score?
Target trial emulation
Methods at a glance
Recorded assessment- Confounding adjustmentPropensity scores
- Covariate balance confirmedMet
- Outcome assessors blindedNot reported
- Comparable start of follow-upMet
- Adequate statistical powerNot applicable
- Prospective registrationNot met
Not reported does not mean not done. Checks have different weights; this is not a count of boxes ticked.
How to read this assessment
The recorded methods are shown alongside the published score. A verified point-by-point calculation is not available for this version of the appraisal.
Checklist from the stored appraisal. “Not met” describes the recorded criterion; it does not always produce a deduction. This overview supports reading the full study.
For journal club
1.This is a retrospective, non-randomised comparison using administrative EHR data with no direct measurement of bone mineral density, falls, physical activity, or medication adherence beyond fill counts; how much could residual confounding (E-value 1.83) explain an HR of 0.79?
2.If GLP-1 RAs are confirmed to lower fracture risk in patients with diabetes but not in those without it, should orthopaedic surgeons or endocrinologists factor fracture risk into the decision to prescribe GLP-1 RAs versus other second-line diabetes agents?
Original publication title
Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes